Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease

被引:82
作者
Ruffillo, Gabriela [1 ]
Fassio, Eduardo [1 ]
Alvarez, Estela [2 ]
Landeira, Graciela [1 ]
Longo, Cristina [1 ]
Dominguez, Nora [1 ]
Gualano, Gisela [1 ]
机构
[1] Hosp Nacl Prof Alejandro Posadas, Liver Unit, Buenos Aires, DF, Argentina
[2] Hosp Nacl Prof Alejandro Posadas, Pathol Serv, Buenos Aires, DF, Argentina
关键词
Nonalcoholic steatohepatitis; Severe liver fibrosis; Advanced liver fibrosis; Noninvasive prediction of fibrosis; Prognosis of NAFLD; NATURAL-HISTORY; HEPATIC STEATOSIS; UNITED-STATES; RISK-FACTORS; HEPATOCELLULAR-CARCINOMA; GENERAL-POPULATION; PREVALENCE; STEATOHEPATITIS; SYSTEM; VALIDATION;
D O I
10.1016/j.jhep.2010.06.028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background & Aims: Liver biopsy (LB) is the only means to evaluate fibrosis in NAFLD. Two scoring systems, NAFLD fibrosis score and BARD score, were proposed to separate cases with and without severe fibrosis (SF). Our aim was to compare the utility of both scores in patients with biopsy-proven NAFLD. Methods: 138 consecutive patients of our series were included (67 male, median age 49 years). A NAFLD fibrosis score lower than -1.455 would exclude SF. A score greater than 0.676 would predict SF. An intermediate score is defined as indeterminate. The BARD score ranges from 0 to 4. Scores 0-1 are considered to have a high negative predictive value (NPV) for SF. The results of the scores were compared with LB staging. NPV, positive predictive value (PPV) and area under the ROC curve (AUROC) were calculated for both systems. Results: A total of 37 patients had SF. NAFLD fibrosis score was indeterminate in 42 cases. Among the 91 patients with low score, 74 did not have SF but 17 patients had SF. All of 5 patients with a high score had SF. Sensitivity was 22.7%; specificity, 100%; NPV, 81.3%; and PPV, 100%. The BARD score was low in 96 patients and high in 42. Among the 96 patients with a low score, 78 did not have SF but 18 did. Among 42 patients with a high score, 19 had SF. Sensitivity was 51.4%; specificity, 77.2%; NPV, 81.3%; and PPV, 45.2%. AUROC were 0.68 (95% CI, 0.57-0.78) and 0.67 (95% CI, 0.56-0.77) for NAFLD fibrosis and BARD scores, respectively. Conclusions: Both systems were useful in identifying patients without SF (NPV 81.3%) but the BARD score is easier to estimate and does not have indeterminate results. (C) 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:160 / 163
页数:4
相关论文
共 32 条
[1]
The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies [J].
Adams, LA ;
Sanderson, S ;
Lindor, KD ;
Angulo, P .
JOURNAL OF HEPATOLOGY, 2005, 42 (01) :132-138
[3]
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[4]
Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study [J].
Bedogni, G ;
Miglioli, L ;
Masutti, F ;
Tiribelli, C ;
Marchesini, G ;
Bellentani, S .
HEPATOLOGY, 2005, 42 (01) :44-52
[5]
Prevalence of and risk factors for hepatic steatosis in northern Italy [J].
Bellentani, S ;
Saccoccio, G ;
Masutti, F ;
Crocè, LS ;
Brandi, G ;
Sasso, F ;
Cristanini, G ;
Tiribelli, C .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (02) :112-117
[6]
Projection of diabetes burden through 2050 - Impact of changing demography and disease prevalence in the US [J].
Boyle, JP ;
Honeycutt, AA ;
Narayan, KMV ;
Hoerger, TJ ;
Geiss, LS ;
Chen, H ;
Thompson, TJ .
DIABETES CARE, 2001, 24 (11) :1936-1940
[7]
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[8]
Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x
[9]
Insulin resistance: A metabolic pathway to chronic liver disease [J].
Bugianesi, E ;
McCullough, AJ ;
Marchesini, G .
HEPATOLOGY, 2005, 42 (05) :987-1000
[10]
Expanding the natural history from cryptogenic cirrhosis to of nonalcoholic steatohepatitis: Hepatocellular carcinoma [J].
Bugianesi, E ;
Leone, N ;
Vanni, E ;
Marchesini, G ;
Brunello, F ;
Carucci, P ;
Musso, A ;
De Paolis, P ;
Capussotti, L ;
Salizzoni, M ;
Rizzetto, M .
GASTROENTEROLOGY, 2002, 123 (01) :134-140